Targeting autophagy to sensitive glioma to temozolomide treatment
Temozolomide (TMZ), an alkylating agent, is widely used for treating primary and recurrent high-grade gliomas. However, the efficacy of TMZ is often limited by the development of resistance. Recently, studies have found that TMZ treatment could induce autophagy, which contributes to therapy resistan...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736617/ |